Jilin Province Huinan Changlong Bio-pharmacy Company Limited
HKSE 8049.HK
Jilin Province Huinan Changlong Bio-pharmacy Company Limited EBIT for the year ending December 31, 2023: USD 28.01 M
-
Jilin Province Huinan Changlong Bio-pharmacy Company Limited EBIT for the year ending December 31, 2022 was USD 28.67 M, a 2.55% change year over year.
-
Jilin Province Huinan Changlong Bio-pharmacy Company Limited EBIT for the year ending December 31, 2021 was USD 27.95 M, a 21.03% change year over year.
-
Jilin Province Huinan Changlong Bio-pharmacy Company Limited EBIT for the year ending December 31, 2020 was USD 23.10 M, a -8.31% change year over year.
-
Jilin Province Huinan Changlong Bio-pharmacy Company Limited EBIT for the year ending December 31, 2019 was USD 25.19 M, a -7.05% change year over year.
| Date | EBIT | EBITDA | Net Income | EPS (Diluted) |
|---|
Don’t Miss A Beat
| CEO | Mr. Hong Zhang |
| IPO Date | May 24, 2001 |
| Location | Hong Kong |
| Headquarters | Grand Plaza, Office Tower Two |
| Employees | 678 |
| Sector | Healthcare |
| Industries | |
Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, pills, Chinese medicine pretreatment and extraction products, powders for injections, lyophilized powder for injections, small volume injection solutions, APIs, and granules. The company markets its products under the Changlong and Qing Tong brands. The company was formerly known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited. Jilin Province Huinan Changlong Bio-pharmacy Company Limited was founded in 1989 and is based in Kowloon, Hong Kong.
Past 5 years
StockViz Staff
February 3, 2025
Any question? Send us an email